Literature DB >> 33166087

Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.

Débora C Bastos1,2, Caroline F Ribeiro3, Thomas Ahearn4, Jéssica Nascimento1, Hubert Pakula3, John Clohessy5, Lorelei Mucci4, Thomas Roberts6, Silvio M Zanata7, Giorgia Zadra1, Massimo Loda1,3,8,9.   

Abstract

Loss of the tumor suppressor gene Pten in murine prostate recapitulates human carcinogenesis and causes stromal proliferation surrounding murine prostate intraepithelial neoplasia (mPIN), which is reactive to microinvasion. In turn, invasion has been shown to be regulated in part by de novo fatty acid synthesis in prostate cancer. We therefore investigated the effects of genetic ablation of Fasn on invasive potential in prostate-specific Pten knockout mice. Combined genetic ablation of Fasn and Pten reduced the weight and volume of all the prostate lobes when compared to single knockouts. The stromal reaction to microinvasion and the cell proliferation that typically occurs in Pten knockout were largely abolished by Fasn knockout. To verify that Fasn knockout indeed results in decreased invasive potential, we show that genetic ablation and pharmacologic inhibition of FASN in prostate cancer cells significantly inhibit cellular motility and invasion. Finally, combined loss of PTEN with FASN overexpression was associated with lethality as assessed in 660 prostate cancer patients with 14.2 years of median follow-up. Taken together, these findings show that de novo lipogenesis contributes to the aggressive phenotype induced by Pten loss in murine prostate and targeting Fasn may reduce the invasive potential of prostate cancer driven by Pten loss.
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Entities:  

Keywords:  FASN; GEMM; PTEN; invasion; prostate cancer

Year:  2020        PMID: 33166087      PMCID: PMC7898611          DOI: 10.1002/path.5587

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  71 in total

Review 1.  Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.

Authors:  F P Kuhajda
Journal:  Nutrition       Date:  2000-03       Impact factor: 4.008

Review 2.  The PI3 kinase signaling pathway in prostate cancer.

Authors:  Aymen A Elfiky; Zhenyang Jiang
Journal:  Curr Cancer Drug Targets       Date:  2013-02       Impact factor: 3.428

Review 3.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

4.  Expression signature of the mouse prostate.

Authors:  Isabelle M Berquin; Younong Min; Ruping Wu; Hong Wu; Yong Q Chen
Journal:  J Biol Chem       Date:  2005-07-29       Impact factor: 5.157

5.  The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas.

Authors:  Michelle Agostini; Luciana Y Almeida; Débora C Bastos; Rose M Ortega; Fernanda S Moreira; Fabiana Seguin; Karina G Zecchin; Helena F Raposo; Helena C F Oliveira; Nivea D Amoêdo; Tuula Salo; Ricardo D Coletta; Edgard Graner
Journal:  Mol Cancer Ther       Date:  2013-12-20       Impact factor: 6.261

6.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

7.  Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model.

Authors:  H-W Chen; Y-F Chang; H-Y Chuang; W-T Tai; J-J Hwang
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-09       Impact factor: 5.554

Review 8.  PTEN Mouse Models of Cancer Initiation and Progression.

Authors:  Yu-Ru Lee; Pier Paolo Pandolfi
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915

9.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

10.  Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases.

Authors:  Mario De Piano; Valeria Manuelli; Giorgia Zadra; Jonathan Otte; Per-Henrik D Edqvist; Fredrik Pontén; Salpie Nowinski; Athanasios Niaouris; Anita Grigoriadis; Massimo Loda; Mieke Van Hemelrijck; Claire M Wells
Journal:  Oncogene       Date:  2020-03-05       Impact factor: 9.867

View more
  3 in total

Review 1.  Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Authors:  Nuria Gómez-Cebrián; José Luis Poveda; Antonio Pineda-Lucena; Leonor Puchades-Carrasco
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 2.  The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.

Authors:  Eleazer P Resurreccion; Ka-Wing Fong
Journal:  Metabolites       Date:  2022-05-27

Review 3.  Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?

Authors:  Laura A Sena; Samuel R Denmeade
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 12.701

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.